Pathophysiology and potential treatment of uremic sarcopenia
Top Cited Papers
Open Access
- 1 March 2026
- journal article
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 45 (2) , 160-173
Abstract
Sarcopenia, commonly found in the elderly and characterized by the loss of skeletal muscle mass, decreased muscle strength, and reduced physical performance, draws attention because it often leads to frailty, an increased risk of falls and fractures, and higher morbidity and mortality. Patients with chronic kidney disease (CKD) usually suffer from malnutrition, physical inactivity, inflammation, metabolic acidosis, insulin resistance, and other hormonal changes, which are all aggravating factors of sarcopenia. Therefore, the prevention, early detection, and adequate management for sarcopenia in patients with CKD help to improve their quality of life, prevent various complications and disabilities, as well as to reduce the risk of major morbidities and death. We reviewed the diagnosis and prevalence of sarcopenia in CKD and discussed the risk factors, etiology, pathophysiology, clinical impacts, and present treatment strategies for sarcopenia in CKD. The applications of exercises along with nutritional interventions, correction of metabolic acidosis caused by CKD, anabolic hormones, appetite stimulants, and other agents in uremic sarcopenia were discussed. Early detection and adequate management help to improve muscle strength and mass and enhance physical performance, therefore improving the quality of life and reducing mortality in CKD patients with sarcopenia.Keywords
This publication has 75 references indexed in Scilit:
- Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta‐analysisJournal of Cachexia, Sarcopenia and Muscle, 2024
- Effects of correcting metabolic acidosis on muscle mass and functionality in chronic kidney disease: a systematic review and meta‐analysisJournal of Cachexia, Sarcopenia and Muscle, 2023
- Should we consider sarcopenia in pediatric patients with chronic kidney disease? A preliminary cross-sectional analysisPediatric Nephrology, 2023
- Gut microbes and muscle function: can probiotics make our muscles stronger?Journal of Cachexia, Sarcopenia and Muscle, 2022
- Effects of AST‐120 on muscle health and quality of life in chronic kidney disease patients: results of RECOVERY studyJournal of Cachexia, Sarcopenia and Muscle, 2021
- Effects of hormonal changes on sarcopenia in chronic kidney disease: where are we now and what can we do?Journal of Cachexia, Sarcopenia and Muscle, 2021
- Association of sarcopenia with mortality and end‐stage renal disease in those with chronic kidney disease: a UK Biobank studyJournal of Cachexia, Sarcopenia and Muscle, 2021
- Vitamin D, a modulator of musculoskeletal health in chronic kidney diseaseJournal of Cachexia, Sarcopenia and Muscle, 2017
- Home-based versus center-based aerobic exercise on cardiopulmonary performance, physical function, quality of life and quality of sleep of overweight patients with chronic kidney diseaseClinical and Experimental Nephrology, 2017
- Validation of the SarQoL®, a specific health‐related quality of life questionnaire for SarcopeniaJournal of Cachexia, Sarcopenia and Muscle, 2016